Next Article in Journal
Impact of Health Workers’ Choice of COVID-19 Vaccine Booster on Immunization Levels in Istanbul, Turkey
Previous Article in Journal
Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 5
10.3390/vaccines11050934
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Graves’ Disease after mRNA COVID-19 Vaccination, with the Presence of Autoimmune Antibodies Even One Year Later

by
Fuminori Nakamura
1,
Toru Awaya
1,*,
Masahiro Ohira
2,
Yoshinari Enomoto
1,
Masao Moroi
1 and
Masato Nakamura
1
1
Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, 2-22-36 Ohashi, Meguro-ku, Tokyo 153-8515, Japan
2
Department of Diabetes, Metabolism and Endocrinology, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan
*
Author to whom correspondence should be addressed.
Vaccines 2023, 11(5), 934; https://doi.org/10.3390/vaccines11050934
Submission received: 20 March 2023 / Revised: 17 April 2023 / Accepted: 30 April 2023 / Published: 3 May 2023
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Browse Figures
Review Reports Versions Notes

Abstract

A 45-year-old man who had received his second mRNA COVID-19 vaccination one week earlier was presented to the emergency department with chest discomfort. Therefore, we suspected post-vaccination myocarditis; however, the patient showed no signs of myocarditis. After 2 weeks, he revisited the hospital complaining of palpitations, hand tremors, and weight loss. The patient exhibited high free thyroxine (FT4) (6.42 ng/dL), low thyroid-stimulating hormone (TSH) (<0.01 μIU/mL), and high TSH receptor antibody (17.5 IU/L) levels, and was diagnosed with Graves’ disease. Thiamazole was administered, and the patient’s FT4 levels normalized after 30 days. One year later, the patient’s FT4 is stable; however, their TSH receptor antibodies have not become negative and thiamazole has continued. This is the first case report to follow the course of Graves’ disease one year after mRNA COVID-19 vaccination.
Keywords: ASIA; cross-reactivity; Graves’ disease; mRNA COVID-19 vaccination ASIA; cross-reactivity; Graves’ disease; mRNA COVID-19 vaccination

Share and Cite

MDPI and ACS Style

Nakamura, F.; Awaya, T.; Ohira, M.; Enomoto, Y.; Moroi, M.; Nakamura, M. Graves’ Disease after mRNA COVID-19 Vaccination, with the Presence of Autoimmune Antibodies Even One Year Later. Vaccines 2023, 11, 934. https://doi.org/10.3390/vaccines11050934

AMA Style

Nakamura F, Awaya T, Ohira M, Enomoto Y, Moroi M, Nakamura M. Graves’ Disease after mRNA COVID-19 Vaccination, with the Presence of Autoimmune Antibodies Even One Year Later. Vaccines. 2023; 11(5):934. https://doi.org/10.3390/vaccines11050934

Chicago/Turabian Style

Nakamura, Fuminori, Toru Awaya, Masahiro Ohira, Yoshinari Enomoto, Masao Moroi, and Masato Nakamura. 2023. "Graves’ Disease after mRNA COVID-19 Vaccination, with the Presence of Autoimmune Antibodies Even One Year Later" Vaccines 11, no. 5: 934. https://doi.org/10.3390/vaccines11050934

APA Style

Nakamura, F., Awaya, T., Ohira, M., Enomoto, Y., Moroi, M., & Nakamura, M. (2023). Graves’ Disease after mRNA COVID-19 Vaccination, with the Presence of Autoimmune Antibodies Even One Year Later. Vaccines, 11(5), 934. https://doi.org/10.3390/vaccines11050934

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop